DOCSLIB.ORG

Head and Neck Mucosal Melanoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Head and Neck Mucosal Melanoma www.melanomafocus.com Head and Neck Mucosal Melanoma Information for patients and carers Introduction Head and Neck The information in this leaflet relates specifically to melanomas of the head Mucosal and neck mucous membranes. The leaflet summarises a guideline (melanomafocus. Melanoma com/activities/mucosal-guidelines/mucosal- melanoma-resources) developed by experts in the field to advise cancer specialists who treat patients with this condition and is based upon the best evidence available. Skin What is it? cancers can also develop in the same areas of Melanoma develops if there is uncontrolled These melanomas are different in several the body, in the skin rather than in the mucous growth of melanocytes, the cells responsible ways from skin melanomas. For example, membranes. These are known as cutaneous for pigmenting (darkening) the skin. Mucosal while the risk of getting skin melanoma is melanomas and are not covered by this melanoma is a kind of melanoma that increased by too much exposure to the sun, guideline. If you have been diagnosed with occurs in mucous membranes. These are there appears to be no link between sunlight a skin (cutaneous) melanoma please refer to the moist surfaces that line cavities within and mucosal melanomas. No specific causes the NICE guideline (nice.org.uk/guidance/ the body. Mucosal melanomas can occur in or links with lifestyle have been found for ng14) and the other organisations listed at the the mouth (oral mucosal melanoma), nasal mucosal melanoma and as far as we know end of this leaflet. passages (sinonasal mucosal melanoma) there is nothing you can do to prevent it. or very occasionally the throat (pharngeal/ It also appears that mucosal melanoma The number of medical terms has been kept laryngeal mucosal melanoma) as well as in tumours are different from skin melanoma to a minimum. If you come across a term you other parts of the body including in the eye tumours. This means that some treatments don’t understand, please see the definitions or around the genital and rectal areas. This for skin melanomas may not be as effective and abbreviations section at the end of the leaflet discusses mucosal melanomas of the for mucosal melanoma and the outlook document or ask your consultant or nurse. head and neck. There are other guideline (prognosis) for mucosal melanomas is not as documents by Melanoma Focus which good as for skin melanomas. The prognosis cover eye melanomas (melanomafocus. will be different depending on whether the com/activities/um-guidelines-resources) tumour can be fully removed surgically and and ano-uro-genital mucosal melanomas whether it has spread. If you would like more (melanomafocus.com/activities/mucosal- information about your individual situation, guidelines/mucosal-melanoma-resources). you should discuss this with your clinical team. Mucosal melanomas are very rare: in the Surveillance Epidemiology and End Results (SEER) database which registered melanomas over 22 years, only about 1 melanoma in 100 was a mucosal melanoma. The majority of melanomas grow within the skin. Mucosal melanomas can be more complicated to treat than skin melanomas as they are often diagnosed later. This is because they are in less visible places and because they are often not pigmented (darker), which makes them even more difficult to spot. B 1 What are the symptoms? Going to the hospital Diagnosis, staging and prognosis Questions you may wish to The most common places to have a mucosal Tests and examination The clinical team will make a diagnosis based melanoma of the head and neck region are on the results of your tests and medical ask about your diagnosis and At the hospital the consultant will examine in the nose, including the sinuses, or the examination. If you are diagnosed with a prognosis you, including the lump, and your neck. You mouth. More uncommonly they occur in the mucosal melanoma, your cancer will be should also have a CT or MRI scan and a What are you looking for in the larynx. As with skin melanomas, there may evaluated according to a process known biopsy where they take a small sample of the biopsies? be an area which is pigmented (darker) but as staging. The stage indicates whether the lump to examine under a microscope. What is the difference between a CT this is NOT always the case. The symptoms cancer has spread in your body and, if so, scan, MRI scan and a PET scan – what are those often associated with less serious If the consultant makes a diagnosis of head where. This staging process will help you and do each show? conditions and include: and neck mucosal melanoma, you would the cancer team make decisions about your normally have a PET-CT scan of your body to future treatment. What stage is my cancer at and what is ● Nosebleeds out of one nostril only that check whether the cancer has spread. There my prognosis? have occurred several times over at least a For the staging, the UICC (Union for are several specific genes which have been 3-week period International Cancer Control: www.uicc.org) Are any gene mutations involved in my identified that may be involved in some, but TNM staging system is used. In addition to cancer? ● Blockage of one nostril, which nose drops not all, mucosal melanoma tumours. The other information the team should record in What is the best treatment available haven’t helped and which have occurred pathologist should test the tissue sample particular: several times or for a long time over at least from the biopsy to see if one of these to me? a 3-week period identified genes is involved in your cancer as ● Location of the primary (original) tumour What sort of health problems might I this will help decide the best treatment for ● have? And what are the plans I need to ● A lump on the tongue or in the mouth Primary Tumour size and extent of tumours you, now and in the future. put in place to be prepared? that may or may not bleed or be darkly ● Lymph Node involvement (whether or not pigmented that is growing bigger and has the cancer has spread to the nearby lymph What supportive services are available been there for at least 3 weeks nodes (also called glands) to me and may I have their contact details for future reference? ● A mouth ulcer which hasn’t got better in ● Presence or absence of distant Metastasis 3 weeks (whether or not the cancer has spread to Can you recommend leaflets or distant areas of the body). websites with information on my ● Unexplained hoarseness which hasn’t got condition? better in 3 weeks The cancer team will make a prediction of the outcome of your cancer – your prognosis Are there any clinical trials available ● Swollen glands in the neck which haven’t – based on the results of your tests and that I might be suitable for? got better in 3 weeks examination and on what happened to others If you have any of these symptoms and your who have had similar cancers. GP cannot find another cause, you should be If you and/or a relative or carer want to have referred quickly (normally within about two a full discussion about your prognosis, make weeks) to a specialist head and neck clinic this clear to someone from the cancer team. with experience of this condition, and usually It will mean that your appointments will be to a head and neck surgeon, for tests and more informative and will enable you to be further evaluation. It is most important that the more involved in planning your treatment team you see regularly treats patients with and other aspects of your life. On the other this condition. As it is so rare, you may need to hand you may wish to take it ‘one step at a travel to a specialist centre rather than attend time’. Whatever your decision, you will be fully your local hospital. supported by the cancer team. 2 3 ● How to make an appointment with the Adjuvant (Extra) therapy consultant quickly should you run into Questions you may wish to Some questions you may wish problems You are likely to be offered adjuvant (extra) ask about your visits to ask about your treatment therapy to reduce the likelihood that ● About referral to support services (for How often will I have appointments at How should I expect to feel after my the cancer comes back after it has been example, supportive care services and the cancer centre? surgery? removed entirely by surgery. (A ‘belt and support groups) should you need them at braces’ approach!). Recently there have been What sort of support will I need at any point in your treatment What will the recovery time be? advances in the treatment of skin melanomas these appointments? ● Written information Will I be able to carry on with life as with immunotherapy. Immunotherapy How long will I be at the centre each normal? stimulates your body to fight the cancer. time? What will be the effects of my surgery? Immunotherapy doesn’t work for everyone What further signs and symptoms Treatment and there can be potentially severe, but What symptoms should I look out for, should I look out for? manageable, side effects. The first line of treatment for a mucosal indicating whether the surgery has What symptoms should I report melanoma is surgery, which should be done worked or not? However, because mucosal melanomas are urgently? by a surgeon who is very experienced in so rare, scientists are still uncertain whether What support will I need after surgery? complex head and neck surgery and is based these treatments work in the same way as How and who should I contact if I need in a centre where there is support from an Am I likely to need rehabilitation? with skin melanomas.
Load more

Recommended publications
  • Sinonasal Neoplasms Mohit Agarwal, MD,* and Bruno Policeni, MD†
    Sinonasal Neoplasms Mohit Agarwal, MD,* and Bruno Policeni, MD† Introduction benign lesions will usually cause bone remodeling and/or scle- rosis. Loss of bright fat marrow intensity on T1W MR images f Rip Van Winkle went to medical school during the 80s is a sign of bone involvement. Differentiation of benign vs I and woke up today among a meeting of pathologists, he malignant lesions remains a challenge with imaging and excep- would think he was on a different planet and listening to an tions to the previously mentioned features exist. Pathology is “ ” alien language. The once pink and purple world of pathol- required to determine the diagnosis in the majority of cases.7 ogy is now extensively multicolored with an overwhelming Imaging has more to offer than just histological diagnosis, number of immunostains and molecular markers. Histologi- the most important of which is tumor mapping. It must be cal diagnoses now come with an alphanumeric tail, each determined if the tumor is confined within a single sinus or implying the unique gene expression associated with that if there is extension into surrounding structures. Tumors of tumor entity. Needless to say, similar things have happened the maxillary sinuses can extend to the anterior ethmoid fi to the new fourth edition WHO classi cation of sinonasal sinus, nasal cavity, and orbit. Anterior ethmoid tumors can fi (SN) neoplasms, where SMARC B1-de cient carcinoma, involve the frontal sinuses and the nasal cavity. Nasal cavity Nuclear protein testis (NUT) midline carcinoma, and human tumors commonly involve the ethmoid sinus. Posterior eth- papilloma virus (HPV)-related multiphenotypic SN carci- moid tumors tend to involve the sphenoid sinus.7 1 noma have found a place.
    [Show full text]
  • Melanoma Review
    Philip J. Bergman DVM, MS, PhD Diplomate ACVIM-Oncology Director, Clinical Studies, VCA Antech Medical Director, Katonah-Bedford Veterinary Center (#893) 546 North Bedford Rd., Bedford Hills, NY 10507 Office 914-241-7700, Fax 914-241-7708 Adjunct Associate, Memorial Sloan-Kettering Cancer Center, NYC MELANOMA REVIEW Melanomas in dogs have extremely diverse biologic behaviors depending on a variety of factors. A greater understanding of these factors significantly helps the clinician to delineate in advance the appropriate staging, prognosis and treatments. The primary factors which determine the biologic behavior of a melanoma in a dog are site, size, stage and histologic parameters. Unfortunately, even with an understanding of all of these factors, there will be occasional melanomas which have an unreliable biologic behavior; hence the desperate need for additional research into this relatively common (~ 4% of all canine tumors), heterogeneous, but frequently extremely malignant tumor. This review will assume the diagnosis of melanoma has already been made, which in of itself can be fraught with difficulty, and will focus on the aforementioned biologic behavior parameters, the staging and the treatment of canine melanoma. Biologic Behavior The biologic behavior of canine melanoma is extremely variable and best characterized based on anatomic site, size, stage and histologic parameters. On divergent ends of the spectrum would be a 0.5 cm haired-skin melanoma with an extremely low grade likely to be cured with simple surgical removal vs. a 5.0 cm high-grade malignant oral melanoma with a poor-grave prognosis. Similar to the development of a rational staging, prognostic and therapeutic plan for any tumor, two primary questions must be answered; what is the local invasiveness of the tumor and what is the metastatic propensity? The answers to these questions will determine the prognosis, and to be discussed later, the treatment.
    [Show full text]
  • Oral Pathology
    Oral Pathology Palatal blue nevus in a child Catherine M. Flaitz DDS, MS Georgeanne McCandless DDS Dr. Flaitz is professor, Oral and Maxillofacial Pathology and Pediatric Dentistry, Department of Stomatology, University of Texas at Houston Health Science Center Dental Branch; Dr. McCandless has a private practice in The Woodlands, TX. Correspond with Dr. Flaitz at [email protected] Abstract The intraoral blue nevus occurs infrequently in children. This by the labial mucosa (1). Intraoral lesions have a predilection case report describes the clinical features of an acquired blue ne- for females in the third and fourth decades, in contrast to cu- vus in a 7 year-old girl that involved the palatal mucosa. A taneous lesions that normally develop in children. In large differential diagnosis and justification for surgical excision of this biopsy series, only 2% of the oral blue nevi are diagnosed in oral lesion are discussed. (Pediatr Dent 23:354-355, 2001) children and adolescents (1). Similar to their cutaneous coun- terpart, most oral lesions are acquired; however, there are ith the exception of vascular entities, neoplastic isolated reports of congenital examples. lesions with a blue discoloration are an unusual find Clinically, most lesions present as a solitary blue, gray or Wing in children. Although the blue nevus is a blue-black macule or slightly raised nodule that measures less relatively common finding of the skin in the pediatric popula- than 6 mm in size. The margins are often regular but indis- tion, only a few intraoral examples are documented in the tinct and the surface is smooth.
    [Show full text]
  • Melanomas Are Comprised of Multiple Biologically Distinct Categories
    Melanomas are comprised of multiple biologically distinct categories, which differ in cell of origin, age of onset, clinical and histologic presentation, pattern of metastasis, ethnic distribution, causative role of UV radiation, predisposing germ line alterations, mutational processes, and patterns of somatic mutations. Neoplasms are initiated by gain of function mutations in one of several primary oncogenes, typically leading to benign melanocytic nevi with characteristic histologic features. The progression of nevi is restrained by multiple tumor suppressive mechanisms. Secondary genetic alterations override these barriers and promote intermediate or overtly malignant tumors along distinct progression trajectories. The current knowledge about pathogenesis, clinical, histological and genetic features of primary melanocytic neoplasms is reviewed and integrated into a taxonomic framework. THE MOLECULAR PATHOLOGY OF MELANOMA: AN INTEGRATED TAXONOMY OF MELANOCYTIC NEOPLASIA Boris C. Bastian Corresponding Author: Boris C. Bastian, M.D. Ph.D. Gerson & Barbara Bass Bakar Distinguished Professor of Cancer Biology Departments of Dermatology and Pathology University of California, San Francisco UCSF Cardiovascular Research Institute 555 Mission Bay Blvd South Box 3118, Room 252K San Francisco, CA 94158-9001 [email protected] Key words: Genetics Pathogenesis Classification Mutation Nevi Table of Contents Molecular pathogenesis of melanocytic neoplasia .................................................... 1 Classification of melanocytic neoplasms
    [Show full text]
  • Clinical Characteristics of Malignant Melanoma in Central China and Predictors of Metastasis
    1452 ONCOLOGY LETTERS 19: 1452-1464, 2020 Clinical characteristics of malignant melanoma in central China and predictors of metastasis KE SHI1, XURAN ZHU1, ZHONGYANG LIU1, NAN SUN1, LUOSHA GU1, YANG WEI1, XU CHENG1, ZEWEI ZHANG1, BAIHUI XIE1, SHUAIXI YANG2, GUANGSHUAI LI1 and LINBO LIU1 Departments of 1Plastic Surgery and 2Anorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China Received November 5, 2018; Accepted November 13, 2019 DOI: 10.3892/ol.2019.11219 Abstract. Cutaneous malignant melanoma (MM) is the Introduction most malignant type of all skin neoplasms. There is wide variability in the characteristics of MM between patients of Malignant melanoma (MM) is a highly aggressive cancer different races. The aim of the present study was to investigate derived from neural crest melanocytes and occurs most the clinicopathological characteristics of patients with MM in frequently in the skin, digestive tract, eyes, genitals and nasal central China and to assess the value of specific hematological cavity (1-3) The prognosis of patients with MM is poor and and biochemical indices for predicting metastasis. The data the 5-year survival is reported to be <20% (4). Each year, of 167 patients with MM from the First Affiliated Hospital ~20,000 cases of cutaneous MM are reported in China and of Zhengzhou University (Henan, China) were retrospectively the incidence is growing by 3-5% per year (5). The incidence analyzed and compared with the data of patients with MM of MM is lower in China compared with Western countries, available from cBioPortal for Cancer Genomics. Following but survival is shorter in Chinese patients (6,7).
    [Show full text]
  • Mucosal Melanoma: a Clinically and Biologically Unique Disease Entity
    Focused 345 Review Mucosal Melanoma: A Clinically and Biologically Unique Disease Entity Richard D. Carvajal, MDa; Sharon A. Spencer, MDb; and William Lydiatt, MD,c New York, New York; Birmingham, Alabama; and Omaha, Nebraska Key Words of these arise from mucosal surfaces.1–3 Despite a com- Mucosal melanoma, melanoma of the head and neck, anorectal mon cell of origin, MM is a clinical and pathologic entity melanoma, vulvovaginal melanoma, KIT distinct from its more common cutaneous counterpart. MM can arise from any mucosal surface of the body, with Abstract 55% arising from the head and neck, 24% from the ano- Mucosal melanoma (MM) is an aggressive and clinically complex 2 malignancy made more challenging by its relative rarity. Because rectal mucosa, and 18% from the vulvovaginal mucosa. of the rarity of MM as a whole, and because of the unique biology Disease arising from the mucosa of the pharynx, larynx, and clinical challenges of MM arising from each anatomic location, urinary tract, cervix, esophagus, gallbladder, or other mu- understanding of this disease and its optimal management remains cosal sites is less common. limited. The impact of various treatment strategies on disease con- This article summarizes the clinical, pathologic, and trol and survival has been difficult to assess because of the small size of most reported series of MM arising from any one particular site, molecular features, and the diagnostic and therapeutic the retrospective nature of most series, and the lack of a uniform considerations for the management of MM, underscoring comprehensive staging system for this disease. This article summa- the similarities and differences from cutaneous melanoma rizes the clinical, pathologic, and molecular features, and the diag- (CM).
    [Show full text]
  • Lymphatic Invasion and Angiotropism in Primary Cutaneous Melanoma Andrea P Moy, Lyn M Duncan and Stefan Kraft
    Laboratory Investigation (2017) 97, 118–129 © 2017 USCAP, Inc All rights reserved 0023-6837/17 $32.00 PATHOBIOLOGY IN FOCUS Lymphatic invasion and angiotropism in primary cutaneous melanoma Andrea P Moy, Lyn M Duncan and Stefan Kraft Access of melanoma cells to the cutaneous vasculature either via lymphatic invasion or angiotropism is a proposed mechanism for metastasis. Lymphatic invasion is believed to be a mechanism by which melanoma cells can disseminate to regional lymph nodes and to distant sites and may be predictive of adverse outcomes. Although it can be detected on hematoxylin- and eosin-stained sections, sensitivity is markedly improved by immunohistochemistry for lymphatic endothelial cells. Multiple studies have reported a significant association between the presence of lymphatic invasion and sentinel lymph node metastasis and survival. More recently, extravascular migratory metastasis has been suggested as another means by which melanoma cells can spread. Angiotropism, the histopathologic correlate of extravascular migratory metastasis, has also been associated with melanoma metastasis and disease recurrence. Although lymphatic invasion and angiotropism are not currently part of routine melanoma reporting, the detection of these attributes using ancillary immunohistochemical stains may be useful in therapeutic planning for patients with melanoma. Laboratory Investigation (2017) 97, 118–129; doi:10.1038/labinvest.2016.131; published online 19 December 2016 Primary cutaneous melanoma has a propensity for metastasis, However,
    [Show full text]
  • Malignant Melanoma Update 1993
    JOURNAL OF INSURANCE MEDICINE VOLUME 26, No. 2 SUMMER 1994 MALIGNANT MELANOMA UPDATE 1993 CHARLES W. LYNDE, MD, FRCP(C) Acting Head of Dermatology Toronto Western Hospital Assistant Professor of Medidne University of Toron to President Lynde Center for Dermatology Introduction: Statistics of incidence among women. Malignant melanoma is the number one cancer in white women age 25-29, second There has been a dramatic increase in the incidence of most prevalent in women age 30-35, second only to melanoma throughout the world. breast cancer. This rate of increase in the incidence of this disease is not just a specific flare or matter of more In the United States the incidence of melanoma has cases suddenly being reported. almost tripled in the past four decades growing faster than that of any other cancer. It now ranks number eight Melanoma counts for only 5% of the cases of skin can- to all types. No major change in diagnostic criteria can cers but counts for the majority of skin cancer deaths. explain this rapid increase. Approximately 32,000 Americans developed melanoma in 1991 and 6,500 died While the numbers of people getting melanoma has yet of it. In terms of the life time risk, in 1935 it was one in to show much positive change, there are changes in the 1,500 and it is now felt that by the year 2,000, 1 to 75 to 5-year survival rate for those who have the illness. In 90 Americans will develop melanoma of which I in 300 British Columbia, between 1970-74 for example, the will die.
    [Show full text]
  • A Rare Case of Primary Mucosal Melanoma of the Palate
    Sierko et al. Clin Med Rev Case Rep 2016, 3:121 Volume 3 | Issue 8 Clinical Medical Reviews ISSN: 2378-3656 and Case Reports Case Report: Open Access A Rare Case of Primary Mucosal Melanoma of the Palate Elzbieta Sierko1, Aleksander Nobis1, Dominika Hempel2,3, Marek Z Wojtukiewicz2,4 and Ewa Sierko2,3* 1Students’ Scientific Association affiliated with the Department of Oncology Medical University of Bialystok, Poland 2Department of Oncology, Medical University of Bialystok, Poland 3Department of Radiotherapy, Comprehensive Cancer Center in Bialystok, Poland 4Department of Clinical Oncology, Comprehensive Cancer Center in Bialystok, Poland *Corresponding author: Ewa Sierko, Department of Oncology, Medical University of Bialystok, 12 Ogrodowa St., 15-025 Bialystok, Poland, Tel: 48-85-6646734, E-mail: [email protected] Abstract Case Report Melanoma usually occurs on the skin. Only 1% of all melanomas A 65-year-old man treated from skin psoriasis was referred to the affect mucosal membrane of the head and neck with 1951 cases oncology department by dermatologist with the suspicion of palate reported from 1945 to 2011 in the world [1]. The article describes the melanoma. Physical examination showed painless pigmented lesion case of the 65-year-old patient suffered from the palate melanoma present at mucous at the palate durum, palate mole, right buccal that was irradiated on tumor area. The other therapeutic options for mucosa and right upper alveolus (Figure 1a). No enlarged regional melanoma patients were discussed. lymphatic nodes were detected. Excisional biopsy was performed. Keywords Pathological examination proved mucosal lentiginous melanoma. Immunohistochemical analysis revealed that the neoplastic cells Mucosal melanoma, Palate, Radiotherapy were positive for HMB-45, melan-A, S-100 and negative for AE1/ AE3, confirming the diagnosis of melanoma.
    [Show full text]
  • Clinico-Pathological Evaluation of Oral Melanotic Macule, Oral Pigmented Nevus and Oral Mucosal Melanoma
    Rosario Rivera Buery et al.: Evaluation of Oral Melanotic Lesions Journal of Hard Tissue Biology 19[1] (2010) p57-64 © 2010 The Hard Tissue Biology Network Association Printed in Japan, All rights reserved. CODEN-JHTBFF, ISSN 1341-7649 Online ISSIN 1888-828X Original Clinico-pathological Evaluation of Oral Melanotic Macule, Oral Pigmented Nevus and Oral Mucosal Melanoma Rosario Rivera Buery1) ,Chong Huat Siar2), Naoki Katase3), Masae Fujii 3), Han Liu3), Midori Kubota3), Ryo Tamamura3), Hidetsugu Tsujigiwa3) and Hitoshi Nagatsuka3) 1)College of Dentistry, University of the East, Manila, Philippines. 2)Department of Oral Pathology, Oral Medicine and Periodontology, Faculty of Dentistry, University of Malaya, Malaysia. 3)Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama City, Japan. (Accepted for publication, February 8, 2010) Abstract: Focal pigmented melanocytic lesions rarely occur in the oral cavity but should not be taken for granted for they may represent markers or risks for oral mucosal melanoma (OMM). The study investigated the clinical and pathological features of focal pigmented lesions of melanocytic origin focusing on oral melanotic macule (oral MM), oral pigmented nevus (OPN) and OMM. Immunohistochemistry was employed with S100, HMB-45, Melan A, c-kit and Ki-67. Oral MM mostly occurred on the gingiva and buccal mucosa while OPN mostly occurred on the buccal mucosa. OMM occurred on the palate and gingiva. A female gender predilection was observed in oral MM. Most of the benign lesions were less than 6 mm in diameter while OMM had greater than 10 mm in diameter. Benign lesions occurred in almost the same location as that of OMM.
    [Show full text]
  • Download PDF to Print
    320 NCCN Jatin P. Shah, MD, PhD; Sharon Spencer, MD; Andrea Trotti, III, MD; Randal S. Weber, MD; Gregory Wolf, MD; Mucosal Melanoma and Frank Worden, MD of the Head and Neck Overview Mucosal melanoma (MM) is a rare, very aggres- Clinical Practice Guidelines in Oncology sive noncutaneous melanoma that affects the upper David G. Pfister, MD; Kie-Kian Ang, MD, PhD; David M. Brizel, MD; aerodigestive tract, genitourinary tract, and anal/rec- Barbara Burtness, MD; Anthony J. Cmelak, MD; tal region.1 This portion of the NCCN Clinical Prac- A. Dimitrios Colevas, MD; Frank Dunphy, MD; David W. Eisele, MD; Jill Gilbert, MD; Maura L. Gillison, MD, PhD; tice Guidelines in Oncology (NCCN Guidelines) Robert I. Haddad, MD; Bruce H. Haughey, MBChB, MS; for Head and Neck (H&N) Cancers only describes Wesley L. Hicks, Jr., MD; Ying J. Hitchcock, MD; MMs of the H&N, which constitute fewer than 10% Merrill S. Kies, MD; William M. Lydiatt, MD; Ellie Maghami, MD; of melanomas of the H&N.1,2 Note that a separate Renato Martins, MD, MPH; Thomas McCaffrey, MD, PhD; Bharat B. Mittal, MD; Harlan A. Pinto, MD; NCCN Guideline is available for cutaneous melano- John A. Ridge, MD, PhD; Sandeep Samant, MD; ma (see NCCN Guidelines for Melanoma, available Giuseppe Sanguineti, MD; David E. Schuller, MD; in this issue and online at www.NCCN.org). NCCN Clinical Practice Guidelines in Please Note Oncology for Mucosal Melanoma of the The NCCN Clinical Practice Guidelines in Oncology ® Head and Neck (NCCN Guidelines ) are a statement of consensus of the authors regarding their views of currently accepted ap- proaches to treatment.
    [Show full text]
  • Immunohistochemical Study of CD117 in Various Cutaneous Melanocytic Lesions
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 21: 78, 2021 Immunohistochemical study of CD117 in various cutaneous melanocytic lesions ANTONIA RADU1*, CORNELIA BEJENARU1*, ION ŢOLEA2, MINELA AIDA MARANDUCA3*, DANIEL CONSTANTIN BRĂNIŞTEANU4, LUDOVIC EVERARD BEJENARU5, FLORIN DUMITRU PETRARIU6, GABRIELA STOLERIU7 and DACIANA ELENA BRĂNIŞTEANU8 1Department of Pharmaceutical Botany, 2Department of Dermatology, University of Medicine and Pharmacy of Craiova, Craiova 200349; Departments of 3Physiology, and 4Ophthalmology, ‘Grigore T. Popa’ University of Medicine and Pharmacy, Iaşi 700115; 5Department of Pharmacognosy and Phytotherapy, University of Medicine and Pharmacy of Craiova, Craiova 200349; 6Department of Preventive Medicine and Interdisciplinarity, ‘Grigore T. Popa’ University of Medicine and Pharmacy, Iaşi 700115; 7Clinical Department, Faculty of Medicine and Pharmacy, ‘Dunarea de Jos’ University, Galati 800008; 8Department of Dermatology, ‘Grigore T. Popa’ University of Medicine and Pharmacy, Iaşi 700115, Romania Received September 9, 2020; Accepted October 9, 2020 DOI: 10.3892/etm.2020.9510 Abstract. The aim of the present study was to carried melanoma areas. In invasive cutaneous MMs, CD117 expres‑ out a comparative immunohistochemical evaluation of sion tended to decrease with neoplasia progression proceding CD117 (c‑Kit), a biomarker that evaluates both tumor progres‑ into the tumorigenic, vertical growth phase, being lower in the sion and prognosis, in different melanocytic lesions, to profound dermal component of tumors and in nodular MMs. emphasize the significance of this biomarker in malignant To eliminate the epidermal barriers and gain a proliferative melanoma (MM). The study was performed on 55 cases, repre‑ advantage to allow the transition to the vertical growth phase, sented by a control group, which included 5 cases of simple it seems that MM should lose expression of c‑Kit.
    [Show full text]